Multiple Sclerosis (Relapsing-Remitting Type). Multiple sclerosis
Conditions
Interventions
Intervention group: Melatonin administration: Patients receive 5 mg of melatonin daily, one hour before sleep, for 12 weeks..
Sponsors
Qazvin University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: Definitive diagnosis of MS based on McDonald criteria and confirmed by a specialist physician. Age between 18 and 60 years. Diagnosis of Relapsing-Remitting Multiple Sclerosis (RRMS). Suffering from short-term memory disorders detectable by pre-test assessment.
Exclusion criteria
Exclusion criteria: Age less than 18 years or more than 60 years. Lack of written patient consent to participate in the study. Diagnosis of MS types other than Relapsing-Remitting MS (RRMS). Use of other medications that may affect memory or sleep. History of allergy or sensitivity to melatonin. Presence of other chronic conditions such as uncontrolled diabetes or kidney failure. Alcohol or drug use in the past 6 months. Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Short-term visual memory Description: Short-term visual memory is measured using the Colour Wheel Test. This variable refers to the patients' ability to recall and reproduce colours within a short time frame (a few seconds to a few minutes), with evaluation criteria including error rate, response time, and confidence in colour selection. Timepoint: Measurement of outcome variables will be conducted at two time points: initially, before the intervention (pre-test) and then 12 weeks after the start of melatonin use (post-test). Method of measurement: Short-term visual memory: Measured using the Colour Wheel Test, which involves selecting colours on a simulated display screen, with criteria including error rate, response time, and confidence in selection.;Potential side effects of melatonin are recorded through patient reports and clinical examinations by healthcare staff. This variable includes any physical or psychological symptoms reported by patients during the intervention period. Timepoint: Measurement of outcome variables will be conducted at two time points: initially, before the intervention (pre-test) and then 12 weeks after the start of melatonin use (post-test). Method of measurement: Recorded through patient verbal reports and clinical examinations by healthcare staff.;Changes in quality of life are assessed using standard questionnaires (such as health-related quality of life questionnaires). This variable reflects improvements or reductions in general well-being, daily functioning, and patient satisfaction with life. Timepoint: Measurement of outcome variables will be conducted at two time points: initially before the intervention (pre-test) and then 12 weeks after the start of melatonin use (post-test). Method of measurement: Changes in quality of life: Assessed using standard health-related quality of life questionnaires (e.g., SF-36). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactKavosh Ansari Dezfoli
Qazvin University of Medical Sciences
Outcome results
None listed